Suzetrigine, a novel nonopioid analgesic for acute pain

The clinical utility of many analgesics is limited by their nonselective action, which yields desired analgesia at the cost of significant off-target effects across multiple organ systems. Developing non-opioid therapies that act selectively on peripheral nociceptive pathways remains a key goal for achieving effective and safer pain management.

Suzetrigine, a highly selective inhibitor of the voltage-gated sodium channel subtype 1.8 (NaV1.8), represents a novel class of nonopioid analgesics that recently granted the Food and Drug Administration approval for the treatment of moderate to severe acute pain. NaV1.8 is selectively expressed in peripheral sensory neurons, where it plays a critical role in transmitting nociceptive signals from tissue injury. In clinical studies, suzetrigine demonstrated analgesic efficacy comparable to hydrocodone/acetaminophen, combined with the absence of abuse and addictive potential. High patient satisfaction, and a lack of serious adverse effects further support its role in multimodal analgesia.

Suzetrigine shows significant potential to improve the treatment of moderate-to-severe acute pain of both surgical and nonsurgical origin.